432 Early GLP-1 Receptor Agonist Use Is Associated With Reduced Mortality and Neurologic Complications Following Traumatic Brain Injury: A Propensity Score Matched Cohort Study

View at publisher Summarise with VIRAT
Authors: Sean O’Leary, Matias Luis Costa, Christopher C. Young, Peter T. Kan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are widely prescribed for metabolic disease and exhibit neuroprotective effects in preclinical models of traumatic brain injury (TBI). Their real-world impact on post-TBI is not well understood. METHODS: We queried the TriNetX Research Network (2005–2022) to identify adults with focal or diffuse TBI. Patients who initiated GLP-1-RA therapy within 8 weeks of injury were matched 1:1 to controls by demographics and comorbidities. Matched cohorts were analyzed at 6 months (n = 519/group) and 1 year (n = 478/group). TBI-related outcomes included cognitive impairment, seizures, hemorrhagic complications (subarachnoid, intracerebral, and other intracranial hemorrhage), emergency room (ER) visits, need for surgery, and mortality. GLP-1-RA-related adverse effects included gastrointestinal symptoms and pancreatitis. RESULTS: At 6 months, GLP-1-RA users had lower cognitive impairment (4.7% vs. 10.3%, OR 0.43, p = 0.002) and hemorrhagic complications (8.5% vs. 22.1%, OR 0.33, p < 0.001). At 1 year, GLP-1-RA was associated with reduced ER visits (24.3% vs. 33.9%, OR 0.63, p = 0.001), hemorrhagic complications (9.6% vs. 19.0%, OR 0.46, p = 0.008), and mortality (12.2% vs. 21.8%, OR 0.50, p < 0.001). No differences were observed for seizures, cognitive impairment, or surgical intervention. Kaplan-Meier analysis confirmed significantly improved 1-year survival (p = 0.0002), reduced hemorrhagic events (p = 0.0046), and fewer ER visits (p = 0.0002) in the GLP-1-RA group. GLP-1-RA gastrointestinal side effect rates and pancreatitis were similar between groups at all timepoints (all p > 0.05). CONCLUSIONS: Early GLP-1-RA use after TBI was associated with lower mortality, hemorrhagic complications, and ER utilization without increased adverse effects, supporting further investigation in prospective trials.

Fields of Study & Subjects

Traumatic Brain Injury and Neurovascular Disturbances Traumatic Brain Injury Research Diabetes Treatment and Management

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
124–124
Publication date
26 March 2026
Language
EN